TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: awareness of Egyptian population
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Immunesenescent cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Durability during household and community mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the Volume of Ovarian Chocolate Cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Upper gastrointestinal endoscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increased receipt of osteoporosis prescription medications and calcium/vitamin D supplements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Livebirth rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Treatments Prescribed Over the First Study Induction Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Chemotherapies Prescribed Over the First Study Induction Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With MabThera as Maintenance Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With MabThera Maintenance Therapy and at Least One Observation Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: glomerular filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recovery to normal vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of tolerated toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in compliance with exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Number of Panitumumab Infusions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative Dose of Panitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Dose of Panitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participating centers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of trained sonographers in study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: enrolment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: measurement acquisition rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Humoral immune response measured by HI antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of solicited local symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of sickle cell crisis events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of allergic reaction during and after oral food challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Change of hemoglobin level after 12 weeks after oral food challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in skin prick test results 12 weeks after oral food challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on pressure ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ulcer area size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Health and Illness Profile - Achievement Domain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein Angiogram: Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical Coherence Tomography: Retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vasculogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Endothelial function of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombocytopenia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The incidence of fatal hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Number of Place Responsive Neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pain numerical rating scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of subjects relapse free
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Serum Levels of Vitamin D [25(OH)D3]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Autonomic function before and after CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of ring oximetry with PSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activity of one year treatment with zoledronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Checklist Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardio-metabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacodynamics of MOA-728
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year rate of progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Interocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Child executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Strength and muscle gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satiety (inhibition of further eating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective responses on visual analog scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma levels of GSK461364
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of the MRI percent signal change in response to sensory stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical picture using Modified Rankin's Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Inhaled Corticosteroid (ICS) Prescriptions Refilled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: diurnal intraocular pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: removal of uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of patients with skeletal related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change In Chromogranin A (CgA) Biomarker Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change In Serotonin Biomarker Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in arterial oxygenation (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in alveolar arterial oxygen gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With a Four-fold or Greater Increase in NF50 Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression Free Survival (PFS) - First-Line Participants
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) - Second-Line Participants
Endpoint domain: Mortality/survival
Primary endpoint: maximally tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ablated tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hydromorphone consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic Delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness for cDMARDs, tDMARDs, bDMARDs: Assessed by ASDAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State and Trait Anxiety Inventory for Adults (STAI-AD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Satisfaction Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Atopic dermatitis prevalence at M12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a State of Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Achievement of a 'steady state' of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in HIV-1 RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in quality of life before and after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Individual Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Quality of Life in Epilepsy Inventory-10 (QOLIE-10) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in General Anxiety Disorder-7 Screener (GAD-7) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time of onset and completion of disintegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of avoidable Emergency Department re-attendances
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Identification of etiology of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success of DEBDOX-M1 Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collection of Adverse Events Related to Study Device
Endpoint domain: Adverse events/effects
Primary endpoint: Somatic Symptom Scale-China (SSS-CN) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Therapeutic response to HBO at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic response to HBO at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictors of poor outcome including mortality at 1 month
Endpoint domain: Mortality/survival
Primary endpoint: Predictors of poor outcome including mortality at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Predictors of poor outcome including mortality at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Patient's comfort and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Pigmentation at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Pigmentation at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Pigmentation at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: gut microbiome changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Non-Medical Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Motor interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of dyskinesia
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse oximetry reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events and falls during exercise
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Low Molecular Weight Heparin Anti-Xa Activity Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Natremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of complete clearance of the duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of fentanyl used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skeletal muscle imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic fusion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Score of quality of the surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects with no recurrence of heartburn or acid regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of transgender women retained in care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Diagnosis accuracy of cystic pancreatic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Reporting Any Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of the COVID-19 antibody testing kit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin excursion during oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antiretroviral Therapy (ART) Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Male Circumcision Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient/physician satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Swallowing Safety for 10 ml of Thin Liquid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing Safety for 5 ml of Pudding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants commencing anti-HCV treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Living With Heart Failure Quality of Life Score at 6-months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Free of System-related Complications at 6 Months Post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: increase in volume of peripheral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total awakening capability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Gross Motor Function Classification System (GMFCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Gesell Developmental Scale (GDS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone marrow receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C12h of protein bound and unbound blood plasma lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC0-12h of protein bound and unbound blood plasma lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Skin Capacitance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IL-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in AGEs CML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in SRRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S1P levels in allergic and non-allergic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at One Year
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Bayley III Scores in All Three Domains > or Equal to 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mosquito survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Serum ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropsychiatric symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client-Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social Rhythm Metric
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Supportive Accountability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor Burden Reduction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term change of symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peri-operative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Success in finding diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive muco-cutaneous signs of perioperative allergic immediate hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive heart rate of perioperative allergic immediate hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive arterial pressure of perioperative allergic immediate hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive upper gastrointestinal symptoms of perioperative allergic immediate hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive lower gastrointestinal symptoms of perioperative allergic immediate hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: levels of sCD20 in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Left Ventricular End Systolic Volume Index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular global longitudinal strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Eczema Area Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IOP at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes